genOway S.A.
ALGEN.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.65 | 0.29 | -0.13 | 1.85 |
| FCF Yield | 8.42% | 3.08% | 1.24% | -7.49% |
| EV / EBITDA | 9.29 | 7.01 | 73.49 | -22.94 |
| Quality | ||||
| ROIC | -6.86% | 8.31% | 16.68% | -1.40% |
| Gross Margin | -8.55% | 93.80% | -7.68% | -26.72% |
| Cash Conversion Ratio | 2.94 | 1.95 | 3.03 | 1.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.96% | 12.66% | 15.68% | -0.61% |
| Free Cash Flow Growth | 133.89% | 191.89% | 115.46% | 39.40% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 0.47 | 7.76 | -2.78 |
| Interest Coverage | 12.37 | 18.94 | 7.78 | -16.73 |
| Efficiency | ||||
| Inventory Turnover | 11.75 | 1.26 | 15.49 | 17.22 |
| Cash Conversion Cycle | 64.63 | -367.47 | 262.39 | 141.21 |